The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers
Open accessAbstract
SCOPE: The aim of these guidelines is to provide recommendations for decolonizing regimens targeting multidrug-resistant Gram-negative bacteria (MDR-GNB) carriers in all settings. METHODS: These evidence-based guidelines were produced after a systematic review of published studies on decolonization interventions targeting the following MDR-GNB: third-generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), carbapenem-resistant Enterobacteriaceae (CRE), aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant Pseudomonas aeruginosa (XDRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), cotrimoxazole-resistant Stenotrophomonas maltophilia (CRSM), colistin-resistant Gram-negative organisms (CoRGNB), and pan-drug-resistant Gram-negative organisms (PDRGNB). The recommendations are grouped by MDR-GNB species. Faecal microbiota transplantation has been discussed separately. Four types of outcomes were evaluated for each target MDR-GNB:(a) microbiological outcomes (carriage and eradication rates) at treatment end and at specific post-treatment time-points; (b) clinical outcomes (attributable and all-cause mortality and infection incidence) at the same time-points and length of hospital stay; (c) epidemiological outcomes (acquisition incidence, transmission and outbreaks); and (d) adverse events of decolonization (including resistance development). The level of evidence for and strength of each recommendation were defined according to the GRADE approach. Consensus of a multidisciplinary expert panel was reached through a nominal-group technique for the final list of recommendations. RECOMMENDATIONS: The panel does not recommend routine decolonization of 3GCephRE and CRE carriers. Evidence is currently insufficient to provide recommendations for or against any intervention in patients colonized with AGRE, CoRGNB, CRAB, CRSM, FQRE, PDRGNB and XDRPA. On the basis of the limited evidence of increased risk of CRE infections in immunocompromised carriers, the panel suggests designing high-quality prospective clinical studies to assess the risk of CRE infections in immunocompromised patients. These trials should include monitoring of development of resistance to decolonizing agents during treatment using stool cultures and antimicrobial susceptibility results according to the EUCAST clinical breakpoints.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449 · cited 1×
“Population: any patient of any age in any community or healthcare setting with any screening sample yielding one of the following MDR-GNB were included: 3GCephRE, CRE, aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant Pseudomonas aeruginos…”
BackgroundTacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142 · cited 2×
“One of the criteria weighed by WHO experts for prioritization of antibiotic-resistant bacteria was the availability of infection-control measures to reduce the spread of infection in community and healthcare settings.”
BackgroundSelf-citationDecontamination of the digestive tract and oropharynx in ICU patients
de Smet, A. M. G. A., Kluytmans, J. A. J. W., Cooper, B. S., Mascini, E. M., Benus, R. F. J., van der Werf, T. S., van der Hoeven, J. G., Pickkers, P., Bogaers-Hofman, D., van der Meer, N. J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0800394 · Cited by 813
Self-citationThe GRADE system for rating clinical guidelines
Kavanagh, B. P. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000094 · Cited by 246 · cited 1×
“Evidence certainty of controlled studies was classified as high, moderate, low or very low, and recommendation strength was classified as strong or conditional according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [37].”
Method
Cited by
The microbiome-shaping roles of bacteriocins
Heilbronner, S., Krismer, B., Brötz-Oesterhelt, H., & Peschel, A. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00569-w · Cited by 395
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
Self-citationMicrobiota medicine: towards clinical revolution
Gebrayel, P., Nicco, C., Al Khodor, S., Bilinski, J., Caselli, E., Comelli, E. M., Egert, M., Giaroni, C., Karpinski, T. M., Loniewski, I., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03296-9 · Cited by 276
Fu, Y., Dou, Q., Smalla, K., Wang, Y., Johnson, T. A., Brandt, K. K., Mei, Z., Liao, M., Hashsham, S. A., Schäffer, A., et al. (2023) · mLife · doi:10.1002/mlf2.12101 · Cited by 65
Metadata
- Authors
- Tacconelli, E., Mazzaferri, F., de Smet, A. M., Bragantini, D., Eggimann, P., Huttner, B. D., Kuijper, E. J., Lucet, J.-C., Mutters, N. T., Sanguinetti, M., Schwaber, M. J., Souli, M., Torre-Cisneros, J., Price, J. R., & Rodríguez-Baño, J.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 25
- Issue
- 7
- Pages
- 807-817
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2913066827
- Cited by
- 236
- References
- 4
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.